Sandusky, OH -- September 30, 2020 -- InvestorsHub NewsWire --
PAO Group, Inc. (OTC
Pink: PAOG) today indicated plans to reveal new information on
the Company's initiative to expand its cannabis pharmaceutical
treatment research beyond its current focus on Chronic Obstructive
Pulmonary Disease (COPD).
In a media interview scheduled for release on Friday, October
2nd, PAOG Jim DiPrima will highlight a new
pharmaceutical cannabis research expert resource engaged by the
company to bring new industry recognized expertise to move PAOG's
cannabis pharmaceutical asset forward.
On July 30, 2020, PAOG acquired RespRx from Kali-Extracts, Inc.
(OTC
Pink: KALY). RespRx is a cannabis treatment under development
for COPD derived from a patented cannabis extraction method - U.S.
Patent No. 9,199,960 entitled "METHOD AND APPARATUS FOR PROCESSING
HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT."
In an initial scientific evaluation as a treatment for COPD,
RespRx has demonstrated effecting significant increases in
respiration rate, tidal volume and inspiratory air flow rate.
Overall data from the evaluation demonstrated that RespRx can
significantly improve inspiratory lung functions in instances of
moderate pulmonary fibrosis.
With RespRx now in house, PAOG has engaged multiple new experts
from both the university and commercial medical research community
to evaluate the RespRx formula, the formulation process and the
test results.
The expert evaluation has reviewed RespRx in conjunction with
other publicly available cannabis treatment research. Two studies
in particular, both of which highlight the research behind GW
Pharmaceuticals' cannabinoid treatments, shed light on PAOG's wider
opportunity stemming from RespRx, the process to derive RespRx and
the clinical trials to date behind RespRx.
One of the two studies is focused on CBD and the other on THC.
The research seems to indicate CBD has both an impact on
hyper-immune responses that might result in conditions like
a cytokine storm which impacts many
COVID-19 patients, and positive stimulation of immune responses
that fight bad cells. The THC report seems to validate its ability
to relieve pain, but it also indicates immune response manipulation
capabilities to include anti-inflammatory reactions and the
stimulation of immune responses to fight bad cells.
CBD Research - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7173676/
THC Research - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6219460/
In summary, existing publicly available cannabis treatment
research further supports the research findings behind RespRx, and
at the same time, the publicly available research sheds light on
the expanded potential of PAOG's RespRx overall technology.
The growing body of cannabis research is building convincing
evidence behind how specific cannabinoids can beneficially impact
specific immune responses. The research behind RespRx demonstrates
how the process to derive RespRx can be manipulated to target
specific cannabinoid extractions. Accordingly, as advancing
cannabis research unveils further evidence behind how specific
cannabinoids beneficially impact specific immune responses, PAOG is
optimistic that it can utilize its overall cannabis extraction
process to effectively derive formals with high concentrations of
target cannabinoids. Hence, PAOG sees a more broad future of
developing cannabis treatments beyond COPD.
In conjunction with PAOG's acquisition of RespRx, the company
also recently acquired a hemp cultivation business from Puration,
Inc. (OTC
Pink: PURA) to develop a proprietary cultivar to support PAOG's
cannabis pharmaceutical treatment objectives.
PAOG has announced plans with PURA to expand upon PAOG's hemp
cultivation business to develop a proprietary hemp cultivar. PAOG
and PURA are partnering on PURA's
Farmersville Brands initiative.
PAOG's Farmersville cultivar development operation will include
a lab and an environmentally controlled indoor growing facility.
PAOG is working with current cultivars to evolve and produce an
ideal plant with full spectrum, high CBD yields to support ongoing
RespRx development and to support future CBD pharmaceutical
developments.
PAOG is exploring opportunities to engage with university
research in partnership with its hemp cultivar development
initiative.
PURA recently announced a year long initiative to transition
PURA from a CBD sports beverage manufacturer into a hemp
conglomerate built on lifestyle brand with a broad CBD consumer
products reach, and a leading industrial hemp initiative. The brand
name is Farmersville Brands and as part of their strategy, PURA has
entered into a letter of intent (LOI) agreement to acquire 72 acers
of agricultural property in Farmersville, Texas. PURA's year long
initiative includes plans to see the Farmersville Brand strategy
infused with a $100 million investment.
www.paogroupinc.com
Forward-Looking Statements: Certain statements in this news
release may contain forward-looking information within the meaning
of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under
the Securities Exchange Act of 1934, and are subject to the safe
harbor created by those rules. All statements, other than
statements of fact, included in this release, including, without
limitation, statements regarding potential future plans and
objectives of the company are forward-looking statements that
involve risks and uncertainties. There can be no assurance that
such statements will prove to be accurate and actual results and
future events could differ materially from those anticipated in
such statements. Technical complications, which may arise, could
prevent the prompt implementation of any strategically significant
plan(s) outlined above. The Company undertakes no duty to revise or
update any forward-looking statements to reflect events or
circumstances after the date of this release.
CONTACT INFORMATION
Puration, Inc.
Brian Shibley,
(800) 861-1350
info@aciconglomerated.com
Kali (CE) (USOTC:KALY)
Historical Stock Chart
From Dec 2024 to Jan 2025
Kali (CE) (USOTC:KALY)
Historical Stock Chart
From Jan 2024 to Jan 2025
